1 Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-249.
2 Chen W, Zheng R, Baade PD, et al. Cancer statistics in china, 2015. CA Cancer J Clin 2016;66:115-132.
3 Pan JJ, Ng WT, Zong JF, et al. Proposal for the 8th edition of the ajcc/uicc staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer 2016;122:546-558.
4 Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage ii-iva nasopharyngeal carcinoma: Csco and asco guideline. J Clin Oncol 2021;39:840-859.
5 Yang SS, Guo JG, Liu JN, et al. Effect of induction chemotherapy in nasopharyngeal carcinoma: An updated meta-analysis. Front Oncol 2020;10:591205.
6 Chen YP, Tang LL, Yang Q, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: Individual patient data pooled analysis of four randomized trials. Clin Cancer Res 2018;24:1824-1833.
7 Tang M, Jia Z, Zhang J. The evaluation of adding induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: A meta-analysis. Eur Arch Otorhinolaryngol 2021;278:1545-1558.
8 Li WF, Chen NY, Zhang N, et al. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial. Int J Cancer 2019;145:295-305.
9 Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial. Lancet Oncol 2016;17:1509-1520.
10 Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 2019;381:1124-1135.
11 Wu Q, Liao W, Huang J, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma. Oral Oncol 2020;103:104588.
12 Tonin FS, Rotta I, Mendes AM, et al. Network meta-analysis: A technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada) 2017;15:943.
13 Catala-Lopez F, Tobias A, Cameron C, et al. Network meta-analysis for comparing treatment effects of multiple interventions: An introduction. Rheumatol Int 2014;34:1489-1496.
14 Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
15 Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: A new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 2019;10:ED000142.
16 Shim SR, Kim SJ, Lee J, et al. Network meta-analysis: Application and practice using r software. Epidemiol Health 2019;41:e2019013.
17 Neupane B, Richer D, Bonner AJ, et al. Network meta-analysis using r: A review of currently available automated packages. PLoS One 2014;9:e115065.
18 Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase iii multicentre randomised controlled trial. Eur J Cancer 2017;75:14-23.
19 Fountzilas G, Ciuleanu E, Bobos M, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: A randomized phase ii study conducted by the hellenic cooperative oncology group (hecog) with biomarker evaluation. Ann Oncol 2012;23:427-435.
20 Frikha M, Auperin A, Tao Y, et al. A randomized trial of induction docetaxel-cisplatin-5fu followed by concomitant cisplatin-rt versus concomitant cisplatin-rt in nasopharyngeal carcinoma (gortec 2006-02). Ann Oncol 2018;29:731-736.
21 Hui EP, Ma BB, Leung SF, et al. Randomized phase ii trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009;27:242-249.
22 Sun Y, Li W-F, Chen N-Y, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial. The Lancet Oncology 2016;17:1509-1520.
23 Tan T, Lim WT, Fong KW, et al. Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: A randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2015;91:952-960.
24 Peng H, Tang LL, Chen BB, et al. Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal carcinoma: A big-data intelligence platform-based analysis. Oral Oncol 2018;79:40-46.
25 Zeng Z, Yan RN, Tu L, et al. Assessment of concurrent chemoradiotherapy plus induction chemotherapy in advanced nasopharyngeal carcinoma: Cisplatin, fluorouracil, and docetaxel versus gemcitabine and cisplatin. Sci Rep 2018;8:15581.
26 Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase iii randomized intergroup study 0099. J Clin Oncol 1998;16:1310-1317.
27 Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: An update of the mac-npc meta-analysis. Lancet Oncol 2015;16:645-655.
28 Yang Q, Cao SM, Guo L, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase iii multicentre randomised controlled trial. Eur J Cancer 2019;119:87-96.
29 Zhong YH, Dai J, Wang XY, et al. Phase ii trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma. Cancer Chemother Pharmacol 2013;71:1577-1583.
30 Lee AWM, Ngan RKC, Ng WT, et al. Npc-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. Cancer 2020;126:3674-3688.
31 Hong RL, Hsiao CF, Ting LL, et al. Final results of a randomized phase iii trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage iva and ivb nasopharyngeal carcinoma-taiwan cooperative oncology group (tcog) 1303 study. Ann Oncol 2018;29:1972-1979.
32 Frikha M, Auperin A, Tao Y, et al. A randomized trial of induction docetaxel-cisplatin-5fu followed by concomitant cisplatin-rt versus concomitant cisplatin-rt in nasopharyngeal carcinoma (gortec 2006-02). Ann Oncol 2018;29:731-736.
33 Gabani P, Barnes J, Lin AJ, et al. Induction chemotherapy in the treatment of nasopharyngeal carcinoma: Clinical outcomes and patterns of care. Cancer Med 2018;7:3592-3603.
34 OuYang PY, Zhang XM, Qiu XS, et al. A pairwise meta-analysis of induction chemotherapy in nasopharyngeal carcinoma. Oncologist 2019;24:505-512.
35 Zhang Y, Sun Y, Ma J. Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma. Cancer Commun (Lond) 2019;39:39.
36 Zang J, Xu M, Li C, et al. Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of china. J Cancer Res Clin Oncol 2020;146:2369-2378.
37 Zhu J, Duan B, Shi H, et al. Comparison of gp and tpf induction chemotherapy for locally advanced nasopharyngeal carcinoma. Oral Oncol 2019;97:37-43.
38 Yang Y. Cancer immunotherapy: Harnessing the immune system to battle cancer. J Clin Invest 2015;125:3335-3337.
39 Fang W, Yang Y, Ma Y, et al. Camrelizumab (shr-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: Results from two single-arm, phase 1 trials. Lancet Oncol 2018;19:1338-1350.
40 Mai HQ, Chen QY, Chen D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: A multicenter randomized phase 3 trial. Nat Med 2021;27:1536-1543.
41 Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (captain-1st): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2021;22:1162-1174.